Edward Kim, MD
Cardiovascular Disease · Lewiston, IDNPI 1386752913
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 37.8% of the total. Reporting peaked in 2020 at $3,938 and has fallen 91.9% since, to $318 in 2025.
Across 29 payments — averaging $239.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$3K
- Medtronic$2K
- Siemens Medical Solutions USA, Inc.$1K
- Abbott$370
- Boston Scientific$195
- Acutus Medical, Inc.$131
- plus $188 from 4 others
Across 2 payments — averaging $700.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$1K
What the payments were for
- Consulting fees$3,76054%
- Travel & lodging$2,08930%
- Food & beverage$1,08316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 1 | $2,620 |
| Medtronic(2 entities) | 12 | $2,288 |
| Siemens Medical Solutions USA, Inc. | 1 | $1,140 |
| Abbott | 6 | $370 |
| Boston Scientific | 3 | $195 |
| Acutus Medical, Inc. | 1 | $131 |
| Johnson & Johnson | 1 | $101 |
| Penumbra, Inc. | 1 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $25 |
| Eisai Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,932 in reported general payments places this provider in the 85th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 395 | $415,333 |
| XareltoRivaroxaban | 71 | $87,630 |
| Ambrisentan | 13 | $45,036 |
| EntrestoSacubitril/Valsartan | 39 | $41,477 |
| JardianceEmpagliflozin | 38 | $31,351 |
| Metoprolol Succinate | 653 | $11,915 |
| MultaqDronedarone Hcl | 13 | $9,910 |
| Atorvastatin Calcium | 430 | $4,778 |
| Flecainide Acetate | 78 | $3,824 |
| Rosuvastatin Calcium | 241 | $3,647 |
| SotalolSotalol Hcl | 157 | $3,639 |
| ClopidogrelClopidogrel Bisulfate | 230 | $3,241 |
| Sildenafil Citrate | 15 | $3,145 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 68 | $2,434 |
| Amiodarone Hcl | 108 | $2,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $101 | $87,63071 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 cardiovascular disease providers in Idaho.
Other cardiovascular disease in Lewiston
- William RoweLewiston$484
- John OwensLewiston$180
- David HinchmanBoise$324K
- Jacob DelarosaPocatello$226K
- David LaxsonKetchum$135K
- Ryan LongmorePocatello$60K
- Robyn BrydeBoise$27K
- Ronald FritzCoeur D Alene$17K
- Douglas BlankIdaho Falls$11K
- John ChambersIdaho Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.